Seeking Alpha

Merck (MRK +0.5%) gets a boost out of positive comments out of Barron's yesterday, saying that...

Merck (MRK +0.5%) gets a boost out of positive comments out of Barron's yesterday, saying that promising new drugs and a strong dividend should keep investors buying it for some time to come. Moreover, Barron's adds, headcount reductions and synergies from its Schering-Plough acquisition of have gone a long way towards improving the company's margin and growth outlook. Although the stock is trading near 52-week highs, there still may be some life left in the shares.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs